Guangdong Ruigu Biotech Corporation (Ruigu Biotech) provides the

state-a? technology for the pre-clinical/non-clinical innovative drug

DISCOVERY and development, as well as the measurement and

evaluation, including the drug safety assessment. Our Lab is located

in Tiananzhigu Sci-Tech Park, Qingyuan High-tech District, Qingyuan

City, Guangdong Province, China, within one-hour driving from the

Guangzhou Baiyun Airpo?.

Our core team members: Dr. Renke Dai gained his graduated education in the United States of American and obtained the master degree and the doctoral degree there. He worked on his postdoctoral and fellow research in the Molecular Carcinogenesis Laboratory/Metabolism

Laboratory, National Cancer Institute. He also worked as a senior scientist in Bristol-Myers Squibb. His expertise is focusing on the evaluation and assessment of new drug ADME/T-PK properties,

especially in the field of drug-drug interaction risk assessment.

Lately, Dr. Dai was the Principal Investigator and worked as the Director of the Preclinical Research Center as well as the Director of the Laboratory of Drug Metabolism and Pharmacokinetics in Guangzhou Institute of Biomedicine and Health, Chinese Academy of

Sciences. He also was a professor (supervisor for doctoral student) in the School of Bioscience and Engineering, South China University of Technology. He also was the Chief Scientist of the National High-tech Research and Development Program (863 Program); He also participated several R&D projects found from the Ministry of Science and Technology. Additionally, Dr. Dai was also responsible for a number of Sci-Tech research projects found by Guangdong Province or

Guangzhou Science and Technology Department. He gained his experience in both scientific

Dr. Charles Chaojie Zhang (DABT) obtained his PhD degree in the United States of American. His working experience included in Boston Scientific, Lexicon Genetics, and Purdue Pharma as key toxicologist. Extended experience in toxicology and fully responded for toxicology and biocompatibility tests to support the development of new drugs/devices. He is Diplomate of the American Board of Toxicology. Dr. Zhang is proficient in European and American GLP guidelines for animal experiment and familiar with global new drug safety review requirements. He provides scientific guidance and expert review for drug safety evaluation, decision-making, and registration application.

1.(IC50 and/or ki) and/or induction potential evaluation.

2.Drug transporters (P-gp, BCRP, OATP, OAT): substrate properties determination, inhibitory/inducible potential for the drug transporters.

3.Enzyme kinetic parameter determination (different animals: rats, dogs, monkeys, and others).

4.Biomarker studies and measurement.

5.Based on NHP cytokine release syndrome potential evaluation.

6.NHP disease model screening.

7.Xenograft tumor study using nude mice.

8.Animal models of most conventional diseases.

9.Drug-drug interaction risk assessment and decision-making consulting .